Trial intelligence / Profile preview

AC-170 in allergic conjunctivitis

NCT01685242Phase 3Completed

Sponsor
Aciex Therapeutics
Start
Sep 2012
Primary completion
Nov 2012
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of cetirizine in allergic conjunctivitis (AC), sponsored by Aciex Therapeutics. Started Sep 2012; status: completed.

02

Drugs

cetirizine
03

Conditions

allergic conjunctivitis (AC)

Beyond the preview

Go deeper on NCT01685242.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01685242.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call